• In the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or
Obesity trial, the SELECT Investigators tested the hypothesis that the addition of …

Overweight or obesity has been independently associated with increased cardiovascular
risk, yet interventional trials of lifestyle or pharmacologic management strategies for …

More than half the world population is expected to be overweight or obese by the year 2035
[1]. Obesity and atherosclerotic cardiovascular disease have always been a fatal …

Methods SELECT was a multicenter, randomized, double-blind, parallel-group, placebo-
controlled, event-driven trial to evaluate the effect of once-weekly subcutaneous …

Treatment with the glucagon-like peptide 1 receptor agonist semaglutide, administered
subcutaneously at a dose of 2.4 mg once per week, reduces the risk of major cardiovascular …

Background The recently published trial, SELECT (Semaglutide Effects on Cardiovascular
Outcomes in People with Overweight or Obesity) 1, was the first study to demonstrate that …

Background Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse
cardiovascular events (MACE) in people with overweight or obesity, but the effects of this …

Semaglutide, a glucagon-like peptide 1 analogue, reduces the rate of cardiovascular events
in patients with type 2 diabetes mellitus who are at high cardiovascular risk. These findings …

Conclusive evidence have shown the cardiovascular benefits of semaglutide (1 mg weekly)
in people with type 2 diabetes. 1 Recent data have also confirmed the efficacy of high dose …

Background Glucagon-like peptide 1 (GLP-1) receptor agonists have been shown to reduce
major adverse cardiovascular (CV) events (MACE) in people with diabetes. The SELECT …